On the subject of HIV there has been one paper since the one by Lu et al, 2017. It was by Zhang et al, 2019.   https://pubmed.ncbi.nlm.nih.gov/29789664

This is a quote from the paper:

“In this study, we examined the impact of apabetalone on HIV-1 latency. The results indicated that apabetalone could effectively reactivate latent HIV-1 by dissociating BDR4 from the HIV-1 promoter and recruiting Tat to stimulate HIV-1 elongation, and this effect was significantly enhanced when combined with prostratin or SAHA. Furthermore, we demonstrated that apabetalone produced cell cycle arrest at G1/G0 phase and thereby induced the preferential apoptosis of HIV-1 latent cells to promote the death of reactivated reservoir cells. Notably, low HDL cholesterol, lipid metabolism disorders, and cardiovascular diseases are all known side effects of cART and might be prevented by apabetalone. Therefore, apabetalone should be an ideal bifunctional LRA for advancing HIV eradication and reducing the side effects of cART”

Perhaps they or someone else is doing animal experiments and RVX is waitning for the outcome.